FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 265 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers... November 10, 2020 Mom Battling Breast Cancer And Daughter With Alopecia Pose Together To... November 7, 2019 EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib February 1, 2021 Screening People at High Risk for Pancreatic Cancer May Help Them... August 2, 2024 Load more HOT NEWS The link between Down syndrome and childhood leukaemia New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... Making Cancer Clinical Trials Available to More Patients Coronavirus reports – Part 7: “I’m more concerned about the second...
